Translational and personalized oncology bridges the gap between scientific research and real-world cancer care. This field focuses on turning lab discoveries into effective treatments tailored to the unique needs of each patient. Our mission is to bridge the gap between scientific discoveries and their real-world application in the clinic. By combining advanced research, molecular profiling, and clinical insight, we aim to provide customized treatment strategies tailored to each individual patient.
Our work focuses on understanding the biology of cancer at a deeper level, identifying key biomarkers, and developing targeted therapies that improve patient outcomes. We are actively involved in the development of novel anti-cancer drugs, designed to attack tumors with greater precision and fewer side effects.
In addition, we are pioneering new methods for testing drug responses before treatment begins. These innovative approaches allow us to predict how a patient’s cancer will react to specific therapies, increasing the likelihood of success and minimizing unnecessary treatments.
Through a multidisciplinary approach, we are transforming cancer care – making it more precise, effective, and personal.
Research Projects
With no glucose cancer cells may get stronger
Cancer cells are known to consume higher amounts of glucose (Warburg effect or aerobic glycolysis) associated with upregulated expression of genes involved in glucose metabolism. In our experimental work with glucose metabolism, we identified a previously undescribed subpopulation that is able to survive in the absence of glucose supply.
β-hydroxybutyrate as a regulator of Breast Cancer cells metabolism and oncogenicity
One of our key tools is the assembloid model—a cutting-edge 3D culture system that mimics the complexity of human tumors by incorporating cancer cells with supporting stromal and immune components. This model enables us to test drug responses in a patient-specific context, offering a powerful platform for predicting treatment outcomes and guiding personalized therapeutic decisions.